Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Artelo BiosciencesARTL -3.80%32 Operating Cash Flow per Share is $-184.78 as of Jun. 2026. GuruFocus rates ARTL with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,134 Biotechnology companies, Artelo Biosciences ranks better than 55.29% on this metric.
Artelo Biosciences's operating cash flow per share for the
three
months ended in Jun. 2026 was $-10.82.
Artelo Biosciences's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2026 was $-184.78.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 21.90% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 31.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Artelo Biosciences's Operating Cash Flow per Share or its related term are showing as below:
ARTL'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -115.6 Med: 21.9 Max: 44.7
Current: 21.9
During the past 12 years, Artelo Biosciences's highest 3-Year average Operating Cash Flow per Share Growth Rate was 44.70% per year. The lowest was -115.60% per year. And the median was 21.90% per year.
ARTL's 3-Year OCF Growth Rate is ranked better than 55.29% of 1134
companies
in the Biotechnology industry
Industry Median: 17
vs ARTL: 21.90
Artelo Biosciences Operating Cash Flow per Share Related Terms
Artelo Biosciences Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Artelo Biosciences's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artelo Biosciences Operating Cash Flow per Share Chart
ARTL vs PPCB, CLDI, GNPX: Operating Cash Flow per Share Comparison
For the Biotechnology subindustry, Artelo Biosciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artelo Biosciences Price-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Artelo Biosciences's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Artelo Biosciences's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-184.78
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $-184.78 mean?
Artelo Biosciences (ARTL) has a Operating Cash Flow per Share of $-184.78 as of Jun. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Artelo Biosciences and its competitors. According to the industry distribution chart, Artelo Biosciences ranks #507 out of 1134 companies in the Biotechnology industry, placing it in the top 44.7%.
Is Artelo Biosciences' Operating Cash Flow per Share too high?
Artelo Biosciences' current Operating Cash Flow per Share is $-184.78. Based on the distribution chart, Artelo Biosciences ranks #507 out of 1134 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Artelo Biosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Artelo Biosciences' Operating Cash Flow per Share compare to PPCB and CLDI?
According to the Biotechnology industry distribution chart, Artelo Biosciences ranks #507 out of 1134 companies for Operating Cash Flow per Share. This puts Artelo Biosciences in the upper half of its industry. The industry median Operating Cash Flow per Share is 17.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Biotechnology company?
The median Operating Cash Flow per Share among Biotechnology companies is 17.00, based on 1,134 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Artelo Biosciences and its competitors. For the Biotechnology industry, the median Operating Cash Flow per Share is 17.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artelo Biosciences's current Operating Cash Flow per Share is $-184.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artelo Biosciences stock overvalued right now?
Artelo Biosciences (ARTL) has a current Operating Cash Flow per Share of $-184.78. The current Operating Cash Flow per Share is $-184.78. Artelo Biosciences' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Artelo Biosciences (ARTL), the current Operating Cash Flow per Share is $-184.78 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
32GF Score
Get the complete analysis for ARTL
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARTL has been successfully added to your 
